PRESENTATION

Q1 2025 — Presentation

Q1 2025PDF · 29 pages1.9 MB
First-Quarter 2025
Sales and Earnings
Merck & Co., Inc., Rahway, N.J., USA
April 24, 2025

-- 1 of 29 --

Agenda
2
Agenda
Strategy and Business Update
Robert M. Davis
Chairman and Chief Executive Officer
Financial Results and Outlook
Caroline Litchfield
Executive Vice President and Chief Financial Officer
Research Update
Dr. Dean Y. Li
Executive Vice President and President, Research Laboratories
Question & Answer Session

-- 2 of 29 --

3
This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the
safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and
expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to
pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If
underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including
interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost containment; technological advances, new products and patents
attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign
risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation,
including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future
events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements
can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA

-- 3 of 29 --

Strategy and
Business Update
Robert M. Davis
Chairman and Chief Executive Officer
4

-- 4 of 29 --

5
Q1 2025 total company performance and pipeline progress
$15.5B
Q1 Worldwide Sales
Strength in Oncology and Animal Health
Meaningful contributions from new launches
Cardiometabolic
Important results for WINREVAIR from Phase 3 ZENITH trial
Licensed HRS-5346, oral Lp(a) inhibitor, from Hengrui Pharma
Infectious Disease
Results from two Phase 3 switch studies for islatravir + doravirine
for HIV treatment in adults
Oncology
Presentation of data and FDA acceptance of BLA for
subcutaneous pembrolizumab with berahyaluronidase-alfa
FDA acceptance of sBLA for KEYTRUDA in earlier-stage HNSCC

-- 5 of 29 --

6
Delivering the
next wave of
innovation
Well positioned to successfully navigate
through the KEYTRUDA LOE period
Executing Business Development
Actively pursuing additional science-driven
value-creating transactions
Advancing Early- and Late-Phase Pipeline
Nearly tripled late-phase pipeline since 2021
Launching New Growth Drivers
>$50B commercial opportunity by mid-2030s from
recent launches and late-phase pipeline

-- 6 of 29 --

“Confident in our strategic direction,
our commitment to research and
development as the source for
sustainable value-creation, and our
enduring promise to positively
impact patients”
7

-- 7 of 29 --

Financial Results
and Outlook
Caroline Litchfield
Executive Vice President and
Chief Financial Officer
8

-- 8 of 29 --

9
Q1 worldwide performance driven by demand for our innovative portfolio
1. Worldwide Sales includes Other Revenue 2. Excludes sales of GARDASIL in China of $1.3 billion in 1Q24 and $193 million in 1Q25
Human Health
$13.6B-3% decrease
-1% ex-exchange
+5% ex-GARDASIL China2
+7% ex-GARDASIL China, ex-exchange
$15.5B-2% decrease
+1% ex-exchange
+6% ex-GARDASIL China 2
+8% ex-GARDASIL China, ex-exchange
WORLDWIDE SALES1 Animal Health
$1.6B+5% growth
+10% ex-exchange

-- 9 of 29 --

10
Oncology: KEYTRUDA continues to benefit patients and drive growth
KEYTRUDA sales of $7.2B increased 6%,
driven by increased uptake from earlier-stage
cancers and robust demand from metastatic
indications
‒ 	In earlier-stage settings, growth driven by
increased utilization in resectable TNBC, RCC
and NSCLC
‒ 	In metastatic disease, growth driven by
increased use of KEYTRUDA in combination with
Padcev in first-line, locally advanced urothelial
cancer, as well as KEYTRUDA in combination
with chemotherapy in 1L endometrial cancer
‒ 	In the U.S., growth negatively impacted by
~$250M due to timing of wholesaler purchases
1Q23 	1Q24 	1Q25
$5.8B
+24%
$7.2B
+6%$6.9B
+24%1
Growth rates exclude the impact of foreign exchange.
1. Includes ~4 percentage points of negative impact of foreign exchange substantially all of which was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases.

-- 10 of 29 --

11
Oncology: Important contributions across broad portfolio
WELIREG sales grew 63%, driven by increased
uptake in certain adult patients with
previously treated advanced RCC in the U.S
‒ 	Now market leader for treatment of adult
patients with advanced RCC following indicated
prior therapies
Lynparza 1 sales grew 8%, primarily due to
higher demand in the U.S. and certain
international markets
Lenvima 2 sales grew 2%, primarily due to
higher demand in the U.S.
Growth rates exclude the impact of foreign exchange.
1. In collaboration with AstraZeneca 2. In collaboration with Eisai
1Q23 	1Q24 	1Q25
$292M
+7%
$275M
+8%
$312M
+8%
1Q23 	1Q24 	1Q25
$255M
+10%
$232M
+5%
$258M
+2%
1Q23 	1Q24 	1Q25
$85M
+102%
$42M
+128%
$137M
+63%

-- 11 of 29 --

12
Vaccines: Broad vaccines portfolio driving global impact
GARDASIL sales of $1.3B decreased 40%,
driven by continued soft demand in China
where channel inventories remain elevated
‒ 	In the U.S., sales benefitted from price and
demand
‒ 	Outside the U.S. and China, growth driven by
higher overall demand including catch-up cohort
in Japan
CAPVAXIVE sales of $107M, driven primarily
by demand from retail pharmacy segment
VAXNEUVANCE sales of $230M increased
7%, driven by ongoing launches in
international markets, partially offset by
competitive pressures in the U.S.
1Q23 	1Q24 	1Q25
$1.7B
+40%
1Q23 	1Q24 	1Q25
$2.2B
+17%
$1.3B
-40%
$2.0B
+43%
$106M
$219M
+106%
$230M
+7%
Growth rates exclude the impact of foreign exchange.

-- 12 of 29 --

13
Cardiovascular: Successful ongoing launch of WINREVAIR
K
5K
10K
15K
20K
25K
30K
35K
40K
U.S. Launch Progress
Total Prescriptions (TRx)
U.S.:
Continued growth in new patient starts and TRx
‒ >1,400 new patients prescribed in the quarter
‒ ~6,600 total patients prescribed since launch
‒ ~5,200 patients with claims approved by payers started treatment since launch
‒ >38,000 total prescriptions filled since launch
Strong breadth and depth of prescribers
‒ ~1,100 physicians have written at least one prescription since launch
‒ Steady increase in percentage of prescriptions for patients whose background
PAH therapies do not include a prostacyclin
Achieved coverage for >70% of lives since launch
Ex-U.S.:
Progressing with launches
‒ Anticipate securing reimbursement in other European countries in 2H25
Global Q1 sales of $280M

-- 13 of 29 --

14
Animal Health: Robust growth driven by demand for livestock products
Animal Health sales increased 10% to $1.6B
‒ 	Livestock sales grew 16%, driven by higher
demand across all species, as well as benefit
from timing of ruminant sales and inclusion of
sales from recently expanded aqua portfolio
‒ 	Companion Animal sales growth of 3% reflects
price
Growth rates exclude the impact of foreign exchange.
1. Includes ~3 percentage points of negative impact of foreign exchange, of which ~2 percentage points was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases.
1Q23 	1Q24 	1Q25
$1.5B
+5%
$1.5B
+4%1
$1.6B
+10%

-- 14 of 29 --

15
Q1 2025 non-GAAP financial results summary 1
$ in billions, except EPS amounts
1. The company is providing certain 2025 and 2024 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business
performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess
performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee
compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but not as a substitute for or
superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the earnings release. 2. Q1 2024 includes a charge of $0.26 per share for
the acquisition of Harpoon. 3. Q1 2025 GAAP EPS of $2.01
Q1 2025 	Q1 2024 	Change Change
Ex-FX
Sales 	$15.5 	$15.8 	-2% 	+1%
Non-GAAP Gross Margin 	82.2% 	81.2% 	+1.0pts 	+1.5pts
Non-GAAP Operating
Expenses $6.1 	$6.4 	-4% 	-3%
Non-GAAP Tax Rate 	14.2% 	16.1% 	-1.9pts 	N/A
Non-GAAP EPS2,3 $2.22 	$2.07 	+7% 	+12%

-- 15 of 29 --

16
Updated 2025 financial outlook
1. Guidance does not assume any additional significant potential business development transactions.
Prior Guidance 	Updated Guidance 	Key Assumptions
Revenue 	$64.1B to $65.6B 	$64.1B to $65.6B • 	Now assumes ~1 percentage point FX headwind
• 	Implies +0% to +2% nominal (+1% to +3% ex-FX)
Non-GAAP
Gross Margin Rate ~82.5% 	~82.0% • 	Now includes ~$200M of costs related to tariffs
implemented to date
Non-GAAP
Operating Expenses1 	$25.4B to $26.4B 	$25.6B to $26.6B • 	Now includes $200M anticipated upfront payment
related to license agreement with Hengrui Pharma
Other (Income) / Expense 	~$300M to ~$400M of expense 	~$300M to ~$400M of expense
Tax Rate 	~16.0% to 17.0% 	~15.5% to 16.5%
Shares Outstanding 	~2.53B 	~2.51B
Non-GAAP EPS1 	$8.88 to $9.03 	$8.82 to $8.97 • 	Now includes ~$0.06 charge related to license
agreement with Hengrui Pharma
• 	Now assumes negative impact from FX of >$0.20

-- 16 of 29 --

17
Key modeling considerations
GARDASIL
Family1
• 	Following successful HPV catch-up vaccination program in Japan, expect uptake to moderate as future sales will predominantly reflect
the primary age cohort
• 	Therefore, global GARDASIL growth ex-China, while still strong, is anticipated to slow going forward
KEYTRUDA • 	Timing of wholesaler purchases negatively impacted U.S. sales by ~$250M in 1Q25, and will positively impact sales by roughly the same
amount in 3Q25
JANUVIA
Family2
• 	Lowered U.S. list prices at the beginning of 2025 which will reduce rebate amount paid to Medicaid
• 	As a result, expect higher net sales in the U.S. in 2025
• 	1Q25 U.S. sales also benefitted by >$100M from favorable one-time true ups
1. GARDASIL Family includes GARDASIL and GARDASIL 9 2. JANUVIA Family includes JANUVIA, JANUMET and JANUMET XR

-- 17 of 29 --

18
Remain committed to balanced capital allocation strategy
Q1 Spend ($ in billions) 1
Continue to invest in our
pipeline and business while
augmenting our pipeline
with value-enhancing
business development
$3.1
$1.3
$2.0
$1.5
$1.2
After-Tax R&D 	CapEx 	Dividends
Paid
Business
Development
(ex-divestitures)
Share Repurchase
Capital allocation order of priority
1. Reflects quarter spend
2. Reflects R&D excluding Business Development
2

-- 18 of 29 --

Research Update
Dr. Dean Y. Li
Executive Vice President and President,
Research Laboratories
19

-- 19 of 29 --

20
Broadening our impact in cardiometabolic research
WINREVAIR - ZENITH Study 	HRS-5346
• 	First study in PAH to use a primary endpoint comprised entirely of
major morbidity and mortality events
• 	First Phase 3 study in PAH stopped early for ‘overwhelming efficacy’
• 	Profound risk reduction of 76% on composite endpoint of all-cause
death, PAH-worsening related hospitalization (≥24 hours), and lung
transplantation in patients with advanced PAH at high risk of mortality
despite maximally tolerated background therapy vs placebo
‒ 	Early and sustained separation between treatment groups
• 	Loss of clinical equipoise in HYPERION: stopped early and moving to
final analysis based on totality of data in WINREVAIR clinical program to
date
• 	Entered exclusive license agreement
with Hengrui Pharma to develop
investigational oral small molecule
Lp(a) formation inhibitor
• 	Hengrui recently initiated Phase 2
clinical trial in China for HRS-5346
• 	Planning robust global clinical
development program

-- 20 of 29 --

21
Progress across vaccines and infectious disease programs
Vaccines 	HIV
CAPVAXIVE
• 	EC granted approval for active immunization for
prevention of invasive disease and pneumonia caused by
streptococcus pneumoniae in adults
GARDASIL
• 	NMPA of China approved GARDASIL 9 to help prevent
certain HPV-related cancers and diseases in males 16 to
26 years old
• 	Presented detailed results from two pivotal Phase 3 trials
evaluating investigational, once-daily, oral fixed dose
combination of doravirine and islatravir, an
investigational NRTTI, in treatment-experienced adults
with HIV-1 infection at CROI1
‒ 	Both trials met primary efficacy success criteria for non-
inferiority to comparator antiretroviral therapies and primary
safety objectives
‒ 	Plan to submit applications for marketing authorization by
mid-year
1. Conference on Retroviruses and Opportunistic Infections

-- 21 of 29 --

Subcutaneous pembrolizumab
22
Continuing to advance our broad oncology program
1. European Lung Cancer Congress
KEYTRUDA in Earlier Stage 	WELIREG
Announced detailed findings from 3475A-
D77 pivotal Phase 3 trial, evaluating six-
week dosing regimen of the
investigational subcutaneous fixed dose
combination of pembrolizumab and
berahyaluronidase alfa, with
chemotherapy, versus intravenous
KEYTRUDA with chemotherapy at ELCC1
‒ 	Study met dual primary endpoints,
demonstrating non-inferior
pharmacokinetics with a median injection
time of ~2 minutes
‒ 	FDA set PDUFA date of September 23 rd
‒ 	Seeking approval for six-week and three-
week dosing options
‒ 	EMA reviewing application for approval
KEYNOTE-689: FDA granted priority
review for KEYTRUDA as part of a
perioperative treatment regimen for
patients newly diagnosed with resectable,
locally advanced HNSCC
‒ 	FDA set PDUFA date of June 23 rd
If approved, would mark 10th indication
of a KEYTRUDA based regimen for
treatment of certain earlier stage
cancers:
‒ 	Lung: KEYNOTE-671, KEYNOTE-091
‒ 	Renal: KEYNOTE-564
‒ 	Skin: KEYNOTE-054, KEYNOTE-716,
KEYNOTE-629
‒ 	Breast: KEYNOTE-522
‒ 	Cervical: KEYNOTE-A18
‒ 	Bladder: KEYNOTE-057
EC conditionally approved WELIREG for
treatment of adults with:
‒ vHL disease who require therapy for
associated, localized RCC, CNS,
hemangioblastomas, or pancreatic NET
tumors, and for whom localized procedures
are unsuitable based on LITESPARK-004
‒ Advanced clear cell RCC that progressed
following two or more lines of therapy that
included a PD-1 or PD-L1 inhibitor and at least
two VEGF targeted therapies based on
LITESPARK-005

-- 22 of 29 --

23
Key upcoming dates and milestones
JUNE
2
Save the Date:
ASCO Investor Event in Chicago
Upcoming Milestones:
Oncology
• 	KEYNOTE-689 in locally advanced HNSCC - PDUFA date June 23rd
• 	Subcutaneous pembrolizumab - PDUFA date September 23rd
RSV
• 	Clesrovimab in RSV to help protect infants during their first RSV
season - PDUFA date June 10 th
Cardiometabolic
• 	Enlicitide for treatment of hypercholesterolemia – results from three
Phase 3 registration-enabling studies
• 	WINREVAIR
‒ Phase 2 CADENCE study – PCD scheduled for Fall
‒ Phase 3 HYPERION study – final data readout
HIV
• 	Islatravir/doravirine regimen – regulatory filing in U.S
• 	MK-8527 Phase 2a study for PrEP – data readout

-- 23 of 29 --

Q&A
Robert M. Davis
Chairman and Chief Executive Officer
Dr. Dean Y. Li
Executive Vice President and President, Research Laboratories
Caroline Litchfield
Executive Vice President and Chief Financial Officer
Peter Dannenbaum
Senior Vice President, Investor Relations

-- 24 of 29 --

25
Appendix

-- 25 of 29 --

26
Q1 2025 GAAP financial results summary
$ in billions, EPS amounts
1. 1Q24 GAAP results includes $656 million charge, or $0.26 negative EPS impact, for the acquisition of Harpoon
Q1 2025 	Q1 2024 	Change 	Change Ex-FX
Sales 	$15.5 	$15.8 	-2% 	+1%
Operating Expenses1 $6.2 	$6.5 	-5% 	-3%
Tax Rate 	13.9% 	15.9% 	-2.0pts 	N/A
GAAP EPS1 $2.01 	$1.87 	+7% 	+13%

-- 26 of 29 --

27
Capital allocation: Trailing twelve months
$12.4
$3.9
$7.9
$5.1 	$2.3
$0
$3
$6
$9
$12
$15
After-Tax R&D 	CapEx 	Dividends Paid 	Business
Development
(ex-divestitures)
Share
Repurchase
~$20B
Over 5 years, including expanding
manufacturing capacity for Oncology, Vaccines,
and Animal Health. Includes >$11B in the U.S.
Billions
Well-positioned balance sheet
with capacity to fund
additional value-enhancing
business development
opportunities
Order of priority
2
1
E
$1.84 	$1.88 	$1.92
$2.20 $2.44 $2.60 $2.76 $2.92 	$3.08 $3.24
2016 	2017 	2018 	2019 	2020 	2021 	2022 	2023 	2024 	2025E
Dollars per share
+2% 	+2% 	+2%
+11%
+15%
+7% +6% +6% 	+5% +5%
1. Reflects R&D excluding Business Development
2. Includes BD payments reflected in operating cash flow
Over the past 12 months
Capital investments
2024 to 2028
Commitment to the dividend

-- 27 of 29 --

28
Driving value for patients and shareholders by progressing our pipeline
Key regulatory milestones since the last earnings call:
In the U.S., the FDA:
• 	Accepted for review a BLA for subcutaneous pembrolizumab with berahyaluronidase
alfa across all previously approved solid tumor indications for KEYTRUDA based on
3475A-D77
• 	Accepted for priority review the sBLA for KEYTRUDA plus standard of care as
perioperative treatment for resectable locally advanced head and neck squamous cell
carcinoma based on KEYNOTE-689
In the EU, the European Commission:
• 	Approved CAPVAXIVE for active immunization for the prevention of invasive disease
and pneumonia caused by certain types of streptococcus pneumoniae in adults
• 	Approved KEYTRUDA plus chemotherapy as first-line treatment for adult patients
with unresectable non-epithelioid metastatic malignant pleural mesothelioma based on
IND.227/KEYNOTE-483
• 	Conditionally approved WELIREG for the treatment of adult patients with VHL disease
who require therapy for associated, localized RCC, CNS, hemangioblastomas, or pNET,
and for whom localized procedures are unsuitable based on LITESPARK-004
• 	Conditionally approved WELIREG for the treatment of adult patients with advanced
clear cell RCC that progressed following two or more lines of therapy that included a
PD-1 or PD-L1 inhibitor and at least two VEGF-targeted therapies based on
LITESPARK-005
In China, the NMPA:
• 	Approved GARDASIL-9 for the prevention of certain HPV-related cancers and diseases
in males 16-26 years of age
Key data & clinical advancements since the last earnings call:
Presented data for:
• 	Phase 3 ZENITH trial at the American College of Cardiology’s Annual
Scientific Session and Expo demonstrating WINREVAIR significantly
reduced the risk of major morbidity and mortality events in adults with
PAH WHO FC III or IV at high risk of mortality
• 	Pivotal 3475A-D77 Phase 3 trial at the European Lung Cancer
Congress 2025 showing that pembrolizumab with berahyaluronidase
alfa administered subcutaneously (subcutaneous pembrolizumab) was
non-inferior to pembrolizumab IV with respect to PK endpoints, and
results across reported safety and efficacy endpoints were consistent
between the treatment arms
• 	Two pivotal Phase 3 trials at the 32nd Conference on Retroviruses and
Opportunistic Infections evaluating the once-daily, oral, two-drug
regimen of doravirine/islatravir demonstrating non-inferiority and a
similar safety profile to comparator antiretroviral therapies in adults
with virologically suppressed HIV-1
Initiated Phase 3 study evaluating:
• 	Zilovertamab vedotin, an investigational ROR1 antibody-drug
conjugate, for the treatment of patients with previously untreated
diffuse large B-cell lymphoma (waveLINE-010)

-- 28 of 29 --

MK-8591A (doravirine+islatravir) 4
HIV-1 Infection
MK-8591D (islatravir+lenacapavir) 1,4
HIV-1 Infection
LAGEVRIO (MK-4482) 1,5
COVID-19 Antiviral (U.S.)
29
Broad and innovative pipeline to address significant unmet medical needs
As of April 24, 2025
Phase 3
Oncology
MK-1022 (patritumab deruxtecan) 1
NSCLC (EU)
MK-1026 (nemtabrutinib)
Hematological Malignancies
MK-1084 2
NSCLC
MK-1308A (quavonlimab
+pembrolizumab)
RCC
MK-2140 (zilovertamab vedotin)
Hematological Malignancies
MK-2400 (ifinatamab deruxtecan) 1
Esophageal
SCLC
MK-2870 (sacituzumab tirumotecan) 1,3
Breast
Cervical
Endometrial
Gastric
NSCLC
Ovarian
MK-3543 (bomedemstat)
Myeloproliferative Disorders
KEYTRUDA (MK-3475)
Hepatocellular (EU)
Ovarian
SCLC
MK-5684 (opevesostat)
Prostate
LYNPARZA (MK-7339) 1,2
NSCLC
SCLC
LENVIMA (MK-7902) 1,2
Esophageal
V940 (intismeran autogene) 1,2
Melanoma
NSCLC
Infectious Disease
MK-7240 (tulisokibart)
Crohn’s Disease
Ulcerative Colitis
Immunology
Cardiometabolic
MK-0616 (enlicitide decanoate)
Hypercholesterolemia
MK-30006
Diabetic Macular Edema
Ophthalmology
Phase 2
MK-2870 (sacituzumab
tirumotecan) 1,3
Biliary
Bladder
CRC
Neoplasm Malignant
Pancreatic
KEYTRUDA (MK-3475)
Advanced Solid Tumors
Prostate
MK-3475A (pembrolizumab +
berahyaluronidase alfa)
cSCC
Hematological Malignancies
MK-5909 (raludotatug
deruxtecan) 1
Biliary
Bladder
Cervical
CRC
Endometrial
Gastric
Ovarian
Pancreas
RCC
SCLC
V940 (intismeran autogene) 1,2
Bladder
RCC
MK-1022 (patritumab
deruxtecan) 1,3
Biliary
Bladder
Breast
Cervical
CRC
Endometrial
Esophageal
Gastric
HCC
HNSCC
Melanoma
Ovarian
Pancreas
Prostate
MK-1308 (quavonlimab
+pembrolizumab) 2
NSCLC
MK-2400 (ifinatamab deruxtecan) 1
Biliary
Bladder
Breast
Cervical
CRC
Endometrial
HCC
HNSCC
Melanoma
Ovarian
Pancreas
Oncology
V181
Dengue Fever Virus
Vaccines
Infectious Disease
MK-8527
HIV-1 PrEP
MK-8591B (islatravir+MK-8507)
HIV-1 Infection
MK-5475
PH-COPD
MK-6024 (efinopegdutide)
MASH
WINREVAIR (MK-7962)
Pulmonary Hypertension due to
Left Heart Disease
Cardiometabolic
MK-6194
Lupus
Vitiligo
MK-7240 (tulisokibart)
Systemic Sclerosis
Immunology
MK-1167
Alzheimer’s
Neuroscience
Under regulatory review
Oncology
KEYTRUDA (MK-3475)
HNSCC (US, JPN)
Mesothelioma (JPN)
MK-3475A (pembrolizumab +
berahyaluronidase alfa)
Previously Approved Solid Tumors (U.S.)
Previously Approved Tumors (EU)
MK-1022 (patritumab deruxtecan) 1,7
NSCLC (US)
WELIREG (MK-6482)
Advanced RCC (JPN)
Certain VHL Tumors (JPN)
PPGL (US)
Vaccines
CAPVAXIVE (V116)
Pneumococcal Vaccine Adult (JPN)
Infectious Disease
MK-1654 (clesrovimab)
Respiratory Syncytial Virus (US, EU)
Cardiometabolic
WINREVAIR (MK-7962)
Pulmonary Arterial Hypertension (JPN)
1. Being developed in a collaboration 2. Being developed in combination with KEYTRUDA 3. Being developed as monotherapy and/or in combination with KEYTRUDA 4. On partial clinical hold for higher doses of islatravir than those used in current clinical trials
5. Available in the U.S. under Emergency Use Authorization 6. Program is in Phase 2/3 study 7. In June 2024, FDA issued a CRL for the BLA for patritumab deruxtecan. Merck is working with Daiichi Sankyo to address FDA feedback

-- 29 of 29 --